Efficacy and safety of 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1, 2-benzothiazin-3-carboxamide 1,1-dioxide, a rapid-acting meloxicam formulation, for analgesia after orthopaedic surgery under general anaesthesia: a randomized controlled trial
Authors:
- 14 October 2024
- journal article
- research article
- Published by Springer Nature in Inflammopharmacology
- Vol. 32 (6) , 3799-3808
Abstract
Background Postoperative pain management is one of the most challenging treatments after orthopaedic surgery, and improved medical treatment options are urgently needed. This study aimed to evaluate the efficacy and safety of 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1, 2-benzothiazin-3-carboxamide 1,1-dioxide (QP001) for moderate to severe pain following orthopaedic surgery. Methods This randomized clinical trial enlisted patients experiencing moderate to severe pain following orthopaedic surgery in 20 hospitals in China. We allocated randomly 132 participants to receive 30 mg QP001 and 66 participants to receive 0.9% saline pre-surgery. The primary efficacy outcome was the total morphine consumption within 24 h. Results The total morphine consumption in the QP001 group, versus placebo group, was significantly lower over the following 24 h [12.53 (10.51) vs. 26.13 (13.98), P < 0.001]. The total morphine consumption in the QP001 group, versus placebo group, was also significantly decreased over the following 48 h (P < 0.001). The QP001 group, versus placebo, showed a significant decrease in the effective pressing times of the analgesic pump, morphine relief analgesia ratio over the 24 h and 48 h periods and the area under the curve for pain intensity-time as well as a significant prolonged in the time of first pressing the analgesic pump and the time of first morphine rescue analgesia (P < 0.001). The QP001 groups, versus placebo, show no significant difference in adverse events, but the incidence of adverse drug reactions decreased (59.4% vs. 75.8%, P = 0.023). Conclusion QP001 provides analgesia and reduces opioid consumption in patients with moderate to severe pain after orthopaedic surgery, with a favorable safety profile.Keywords
Funding Information
- Natural Science Foundation of Hunan Province (2021JJ31022, 2023JJ30820)
- Nanjing Delova Biotech Co., Ltd
This publication has 31 references indexed in Scilit:
- Preemptive QP001, a fast-acting meloxicam formulation, provides analgesia and reduces opioid consumption following abdominal surgery: a randomized controlled trialInflammopharmacology, 2023
- Efficacy of preemptive analgesia treatments for the management of postoperative pain: a network meta-analysisBritish Journal of Anaesthesia, 2022
- Pharmacokinetics of Meloxicam Tablets in Healthy Chinese Adults in the Fasting and Fed States: A Single‐Site, Single‐Dose, Randomized, Open, 2‐Period, 2‐Sequence, Crossover Bioequivalence StudyClinical Pharmacology in Drug Development, 2021
- Preoperative meloxicam versus postoperative meloxicam for pain control, patients’ satisfaction and function recovery in hip osteoarthritis patients who receive total hip arthroplasty: a randomized, controlled studyInflammopharmacology, 2020
- Meloxicam2020
- Preventing opioid prescription after major surgery: a scoping review of opioid-free analgesiaBritish Journal of Anaesthesia, 2019
- New Advances in Acute Postoperative Pain ManagementCurrent Pain and Headache Reports, 2018
- History of The Joint Commission’s Pain StandardsJAMA, 2017
- Preoperative preemptive drug administration for acute postoperative pain: A systematic review and meta‐analysisEuropean journal of pain, 2016
- Multimodal Pain Management after Total Hip and Knee Arthroplasty at the Ranawat Orthopaedic CenterClinical Orthopaedics and Related Research, 2009